Selected Articles from This Issue

Abstract

Highlights| February 01 2023 Selected Articles from This Issue Author & Article Information Online ISSN: 1557-3265 Print ISSN: 1078-0432 ©2023 American Association for Cancer Research2023American Association for Cancer Research Clin Cancer Res (2023) 29 (3): 503. https://doi.org/10.1158/1078-0432.CCR-29-3-HI Related Content A commentary has been published: Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases A commentary has been published: Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma A commentary has been published: A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma View more A commentary has been published: HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial View less Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record February 1 2023 Citation Selected Articles from This Issue. Clin Cancer Res 1 February 2023; 29 (3): 503. https://doi.org/10.1158/1078-0432.CCR-29-3-HI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search The study from Wilmott and colleagues aimed to identify baseline clinical features associated with the outcomes of patients enrolled in the COMBI-MB phase II study of dabrafenib and trametinib treatment in patients with V600 BRAF-mutant metastatic melanoma with melanoma brain metastases (MBM). Exploratory biomarker analysis also was conducted as part of the synergistic COMBI-BRV trial (BRV116521) to identify molecular and immunological changes associated with dabrafenib in MBM and extracranial (ECM) metastases. Corticosteroid treatment was associated with reduced ICRR and PFS in COMBI-MB, similar to results with immunotherapy for MBM. Baseline corticosteroid treatment is a key factor to consider in MBM patient management and clinical trial design/interpretation. Immune checkpoint blockade (ICB) with nivolumab and ipilimumab has become standard treatment for patients with unresectable malignant pleural mesothelioma (MPM). However, the impact of neoadjuvant ICB in MPM has not yet been evaluated. Lee and colleagues report the results of a randomized, phase II,... You do not currently have access to this content.